- Home
- MCTR vs GALT Comparison
MCTR vs GALT Comparison
Compare MCTR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCTR
- GALT
- Stock Information
- Founded
- MCTR 2014
- GALT 2000
- Country
- MCTR Hong Kong
- GALT United States
- Employees
- MCTR N/A
- GALT N/A
- Industry
- MCTR
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- MCTR
- GALT Health Care
- Exchange
- MCTR NYSE
- GALT Nasdaq
- Market Cap
- MCTR 87.5M
- GALT 83.5M
- IPO Year
- MCTR 2025
- GALT N/A
- Fundamental
- Price
- MCTR $4.72
- GALT $1.31
- Analyst Decision
- MCTR
- GALT Hold
- Analyst Count
- MCTR 0
- GALT 1
- Target Price
- MCTR N/A
- GALT N/A
- AVG Volume (30 Days)
- MCTR 9.0K
- GALT 176.3K
- Earning Date
- MCTR 01-01-0001
- GALT 05-15-2025
- Dividend Yield
- MCTR N/A
- GALT N/A
- EPS Growth
- MCTR N/A
- GALT N/A
- EPS
- MCTR 0.00
- GALT N/A
- Revenue
- MCTR $4,453,234.00
- GALT N/A
- Revenue This Year
- MCTR N/A
- GALT N/A
- Revenue Next Year
- MCTR N/A
- GALT N/A
- P/E Ratio
- MCTR $3,857.49
- GALT N/A
- Revenue Growth
- MCTR N/A
- GALT N/A
- 52 Week Low
- MCTR $3.76
- GALT $0.73
- 52 Week High
- MCTR $12.00
- GALT $3.17
- Technical
- Relative Strength Index (RSI)
- MCTR N/A
- GALT 48.59
- Support Level
- MCTR N/A
- GALT $1.22
- Resistance Level
- MCTR N/A
- GALT $1.36
- Average True Range (ATR)
- MCTR 0.00
- GALT 0.10
- MACD
- MCTR 0.00
- GALT -0.00
- Stochastic Oscillator
- MCTR 0.00
- GALT 29.41
About MCTR CTRL GROUP LTD
CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.